

Anti D Administration in Pregnancy - Full Clinical Guideline

Reference no.: CL/O&G/08

Contents

Section		Page
1	Introduction	1
2	Purpose and Outcomes	1
3	Abbreviations	1
4	Key Responsibilities and Duties	2
5	Risks and Benefits	2
6	Administration of Anti D	2
7	Early Pregnancy (up to 20 weeks gestation)	3
8	Antenatal (after 20 weeks gestation)	4
8.1	Routine Antenatal Anti D Prophylaxis (RAADP)	4
9	Post Natal Patients	4
10	Follow-up for Feto Maternal Haemorrhage (FMH) >4mls	5
11	Documentation	5
12	Monitoring Compliance and Effectiveness	5
13	References	6
14	Documentation Control	7

1. Introduction

Routine Anti D prophylaxis is recommended as treatment option for all pregnant women who are RhD Negative, who are carrying an RhD positive baby predicted by a fetal RhD screening result or when baby's RhD status is unknown. The risk of sensitisation can be reduced by administering anti D immunoglobulin.

Anti-D administration is also recommended in certain circumstances in early pregnancy for ectopic pregnancy, molar pregnancy, miscarriage and abortion.

NB: The term Rhesus is out of date and has been replaced by Rh as in the "Rh Blood Group System"

2. Purposes and Outcomes

To alert all staff caring for women in this group to the fact that sensitisation can occur at any time during pregnancy, but is most common in the third trimester and during childbirth.

3. Abbreviations

CJD - Creutzfeldt-Jakob Disease

CVS - Chorionic Villus Sampling

FMH - Fetal – Maternal Haemorrhage

GAU - Gynaecology Assessment Unit

IM - Intramuscular

iu - International Units

MHHR - Maternity Hand Held Records

PV - Per Vaginum

Rh –ve - Rh D Negative

Rh +ve - Rh D Positive

RAADP - Routine Antenatal anti-D Prophylaxis

4. Key Responsibilities and Duties

All staff caring for women have a duty to ensure women at risk of sensitisation are identified and managed accordingly.

5. Risks and Benefits

Sensitisation has no adverse health effects for the mother and usually does not affect the pregnancy during which it occurs.

Immune anti-D produced by the mother can cross the placenta and bind to Rh D antigen on the surface of foetal red blood cells, these red blood cells are removed from the foetal circulation and anaemia can occur. Severe anaemia can lead to foetal heart failure, fluid retention and swelling (Hydrops), and intrauterine death.

All Anti D immunoglobulin preparations carry a small risk of localised or generalised allergic reactions.

Anti D immunoglobulin used in the UK is prepared from pooled plasma from non-UK blood donors (less risk of variant CJD) and although blood donors are screened there is a small risk of the transmission of blood borne infections.

6. Administration of Anti D

Should normally be given intra-muscularly (ideally into the deltoid).

However it is possible to give subcutaneously if the woman has a bleeding disorder/deranged clotting, this route should be clearly documented by the medical staff.

IV - only 1500iu Rhophylac Anti-D can be administered intravenously in case a large dose of Anti-D is required.

7. Early Pregnancy (up to 20 weeks gestation) in women predicted to be carrying an RhD positive baby by foetal RhD screening or baby's RhD status is unknown.

Termination of pregnancy-

- Termination of pregnancy >10⁺⁰ weeks gestation offer all Rh D negative women anti-D prophylaxis (500iu)
- Medical termination of pregnancy up to and including 10⁺⁰ weeks gestation do not offer anti-D prophylaxis
- Surgical termination of pregnancy up to and including 10⁺⁰ weeks gestation offer anti-D prophylaxis (500iu)

Ectopic pregnancy and miscarriage-

- Surgical management of ectopic pregnancy or miscarriage <13 weeks gestation (up to and including 12⁺⁶ weeks) offer all Rh D negative women anti-D prophylaxis (500iu)
- Medical management of ectopic pregnancy or miscarriage, complete miscarriage or pregnancy of unknown location <13 weeks gestation (up to and including 12⁺⁶ weeks) do not offer anti-D prophylaxis

Molar pregnancy-

- Offer all Rh D negative women <12 weeks gestation (up to and including 11⁺⁶ weeks) anti-D prophylaxis (500iu)

Uterine bleeding (repeated, heavy or with abdominal pain)-

- Offer all Rh D negative women <12 weeks gestation (up to and including 11⁺⁶ weeks) anti-D prophylaxis (500iu)

All Rh D Negative non-sensitised women who are 12 – 20 weeks gestation should be given anti-D (500IU) within 72 hours unless the foetal RhD screen has predicted baby to be RhD negative. The following are classed as sensitising events:

- Invasive pre-natal diagnosis or other intra-uterine procedures
- Ante-partum haemorrhage (PV bleeding)
- External cephalic version
- Abdominal trauma
- Abdominal pain with reasonable grounds for suspicion of abruption

- Intra-uterine death

A Kleihauer test is not required before 20 weeks gestational age (unless patients are undergoing pre-natal diagnostic tests) although a blood group sample is indicated if the maternal blood group is unknown.

Rh D Negative women presenting with continual uterine bleeding between 12-20 weeks gestation should be given 500IU anti-D Ig, at a minimum of 6 weekly intervals.

8. Antenatal (after 20 weeks gestation) in women predicted to be carrying an RhD positive baby by foetal RhD screening or baby's RhD status is unknown.

A Kleihauer test must be taken for each episode listed below even if the woman has recently received anti D immunoglobulin including routine antenatal anti-D prophylaxis (RAADP).

All sensitising episodes after 28 weeks will require further anti-D immunoglobulin.

Anti-D (500iu) IM, should be given to non-sensitised, Rh D Negative women within 72 hours in the event of:

- Amniocentesis, chorionic villus biopsy and cordocentesis
- Antepartum haemorrhage/Uterine (PV) bleeding in pregnancy
- External cephalic version
- Abdominal trauma (sharp/blunt, open/closed)
- Intrauterine death and stillbirth
- In-utero therapeutic interventions (transfusion, surgery, insertion of shunts, laser)
- Miscarriage, threatened miscarriage
- Therapeutic termination of pregnancy
- Delivery – normal, instrumental or Caesarean section

8.1 Routine Antenatal Anti-D Prophylaxis of 1500iu anti-D (IM) to be given at 28-32 (ideally at 28 weeks) weeks gestation, to all non-sensitised Rh D Negative women. A pre-injection blood group and antibody screen is taken as part of University Hospital of Derby and Burton NHS Foundation Trust Antenatal Screening Service. This prophylaxis does not exclude the need for additional anti-D or Kleihauer testing if any of the above events should occur.

9. Post Natal Patients

Non-sensitised Rh D Negative women delivering an Rh D Positive baby should be given 500 iu anti-D within 72 hours after delivery. A Kleihauer test must be performed to determine whether a larger dose is required if significant FMH has occurred at the time of delivery.

NB – If more than 72 hours has elapsed when the need for anti-D in any of the above situations is recognised, then the appropriate dose should still be given as soon as possible, as there may be some benefit for up to 10 days after exposure. The Transfusion

Practitioners must be informed of any missed or late administration of anti-D immunoglobulin as the patient may need a 6 month post-delivery follow up group and screen to check for any immune anti-D production. Missed or late administrations are also externally reportable to Serious Hazards of Transfusion (SHOT).

Rh D Negative mothers, who require cell salvage, need a higher anti-D dose of 1500iu. Blood Bank to be informed.

9.1 Sample requirements at delivery

- Midwife to take **cord blood** from RhD negative women when foetal blood group is predicted to be RhD negative.
- Midwife to take **cord and maternal blood** from RhD negative women when foetal blood group is predicted to be RhD positive or inconclusive.
- Midwife to take **cord and maternal blood** from RhD negative women when foetal group is unknown.

10. Follow-up for Feto-Maternal Haemorrhage (FMH) >4mls

Blood Bank will require a further Kleihauer test 72hrs post administration of anti-D to confirm that the foetal cells have cleared.

11. Documentation

Consent for administration must be obtained and documented in the notes.

If anti-D is declined, this should be documented in the case notes along with the reasons for the decision.

The administration of anti-D antenatally needs to be written in the MHHR, in the designated area on the 'Other investigations carried out during pregnancy' page.

An 'Anti-D required sticker' is to be placed on the Antenatal/Outpatients page as appropriate.



Postnatal administration needs to be documented on the postnatal observation page.

All Anti-D immunoglobulin injections must be issued from the Transfusion Laboratory with accompanying documentation:

- A bag and tag label from which the blue tear off section needs to be fully completed at the time of administration and returned to Blood Bank (this is a legal requirement for traceability for BSQR 2005).
- A white issue form containing details of the patient and dose of anti-D issued (plus baby details when post-delivery) needs to be filed in the MHHR together

12. Monitoring Compliance and Effectiveness

Monitoring requirement	Review to be undertaken on an individual basis through DATIX reporting in the event of sensitisation occurring
Monitoring method	Retrospective case note review
Report prepared by	Continuous reporting process via DATIX
Report sent to	Maternity Risk Group
Report frequency	As required

13. References

BSH Guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn; February 2014

Routine Antenatal Anti D prophylaxis for women who are rhesus D negative. National Institute for Health and Clinical Excellence (NICE) Technology Appraisal 156; August 2008

Abortion Care. National Institute for Health and Clinical Excellence (NICE) NG140; September 2019

Ectopic pregnancy and miscarriage: diagnosis and initial management. National Institute for Health and Clinical Excellence (NICE) NG126; April 2019

RhD Negative Women In Pregnancy – Use of Non-Invasive Fetal RhD Screening to Determine Fetal RhD Status - Clinical Guidelines, KOHA Reference Number: UHDB/AN/03:22/A8

14. Documentaion Control

Reference Number: CL/O&G/08	Version: 7		Status: Final	
Version/Amendment	Version	Date	Author	Reason
	1	May 2001	Mr I Symonds	Introduction of multidisciplinary guidance
	2	Nov 2009	J Steward	In line with NICE Anti D TA 165. And adoption of change in practice
	3	Feb 2013	Judith Beale- Senior Biomedical Scientist/Transfusion Practitioner	Update
	4	Nov 2016	Heather Rankin- Transfusion Practitioner	Review and update
	5	April 2018	Heather Rankin- Transfusion Practitioner	Update to BSH guidance
	6	Sep 2020	Heather Clarke- Blood Bank Manager	Update to include NICE and BSH guidance on all Anti D administration
	7	April 2023	Heather Clarke- Blood Bank Manager	Updated to include cffDNA testing
Intended recipients: All staff with responsibility for caring for pregnant women				
To be read in conjunction with: Information for Women : Rhesus negative v2				
Development / review of guideline			Heather Clarke- Blood Bank Manager	
Consultation with:			Maternity Guidelines Group Gynaecology Guidelines Group	
Approved by:			Maternity Guidelines Group 21.07.23 Gynaecology Guidelines Group 10.08.23 Trustwide Guidelines Group 29/9/2023	
Implementation date:			02/10/2023	
Review date:			September 2026	
Key contact:			Transfusion Practitioner/Joanna Harrison	

